• Explore /
  • Poster
  • / Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: A multicenter open-label phase 1/2a trial.

Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: A multicenter open-label phase 1/2a trial.

Abstract Poster

Authors

null

Galam Leem

Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea

Galam Leem , Sung Ill Jang , Jae-Hee Cho , Jung Hyun Jo , Hee Seung Lee , Moon Jae Chung , Jeong Youp Park , Seungmin Bang , Da-Kyung Yoo , Hyo-Cheon Cheon , Jae-Eun Kim , Kyeong-Pill Lim , In-Hye Jung , Jung-Min Im , Yong Yoon Chung , Seung Woo Park

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03937895

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4080)

DOI

10.1200/JCO.2023.41.16_suppl.4080

Abstract #

4080

Poster Bd #

401

Abstract Disclosures

Similar Posters

First Author: Martin Gutierrez

First Author: Nathalie A. Johnson

First Author: Junho Kang

First Author: Marcus Smith Noel